Navigator Discusses Patient Needs, Barriers to Care

April 2015 Vol 6, No 2



The Journal of Oncology Navigation & Survivorship had the opportunity to speak with Sharon Gentry, RN, MSN, AOCN, CBCN, at the fifth annual Academy of Oncology Nurse & Patient Navigators (AONN+) Conference. A breast health nurse navigator with Novant Health: Derrick L. Davis Cancer Center in Winston-Salem, NC, Ms Gentry is a member of AONN+ as well as its Quality, Outcomes, and Performance Improvement Committee.

What do you think are the most pressing issues facing oncology patients seeking care in your community?
Sharon Gentry (SG): Economics, transportation, and insurance are the biggest issues. We have been hit with some very challenging economic times: the tobacco industry is gone; the furniture industry is also gone. The leading employer in our area is actually the medical center. When each patient comes in, his or her financial needs are evaluated. We are very lucky to have a lot of giving people in our area who can provide some sort of transportation to patients, because there is no formal program in our rural community at this time. Another concern is insurance is- sues among young adults who are deciding whether to sign on for coverage. They feel that they are invincible, that they may not need insurance.

What are the most pressing issues that nurses and physicians who care for these patients face on a regular basis?
SG: Some issues include trying to balance work and other life enjoyments. I often find that people who work with oncology patients are very driven and empathetic. That can often lead to burnout. They have to find a balance between work and life, and they do a very good job at doing that because of the team aspect of care. You will find that sometimes some patients can relate better to other team members; sometimes you work harder with one patient and your colleague may work harder with the next patient. It does balance out.

Are there any barriers to care within the patient community that your institution serves?
SG: The patient community is becoming more multicultural than it ever has before. We are fortunate to have a program we can call on 24 hours a day to help us communicate with patients, which is important from a healthcare perspective. Then we need to think about the support that they are getting back in their own communities, and provide survivorship support and education on cancer prevention as well as prevention support. The challenge is how to serve the needs of a number of different cultures.

What is the most pressing need among patients with cancer and their caregivers?
SG: Having the energy to cope with their disease is a pressing need. It could be that a grandparent is raising his or her grandchildren. It could be that an adult is coping with aging parents and, at the same time, is caring for young children at home. Keeping the balance between everyone

What do you think navigation will look like in 2020 and beyond?
SG: My hope is that each patient who enters a cancer center for care will have access to navigation. A vision would be for them to have access in the community for outreach navigation, that they would have navigation through their diagnostic care, through their treatment care, and also through survivorship and end-of-life care. I hope that we would be making patients, as they come through the door, healthy or healthier as they leave our care, that we are focused on improving the health of the entire population.

Related Articles
Recommendations from the Epithelioid Sarcoma Collaborative: A White Paper
M. Voermans, M. Bui, MD, PhD, E. Conrad, G. D'Amato, MD, J. Goodwin, A. O'Driscoll, MBA, MPA, R. Ratan, MD, MEd, D. Reinke, MS, NP, MBA, E. Peregrine Antalis, MPH, PhD
September 2021 Vol 12, No 9
The authors propose potential solutions to the challenges faced by patients with Epithelioid Sarcoma.
A Nurse Navigator’s Perspective on CDK4/6 Inhibitors
Sharon S. Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN
Rx Profiler – Abemaciclib (Verzenio™), a Novel CDK4/6 Inhibitor, in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
Metastatic breast cancer (MBC) or advanced breast cancer (ABC) signifies that cancer has spread to a distant organ site, either as a progression or a recurrence after a patient has first been diagnosed with an earlier stage of breast cancer. Alternatively, in the case of de novo MBC, MBC or ABC is staged as being metastatic or stage IV at diagnosis.
A Pharmacist’s Perspective on CDK4/6 Inhibitors
Robert Wolf, PharmD
Rx Profiler – Abemaciclib (Verzenio™), a Novel CDK4/6 Inhibitor, in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
Breast cancer is the most common cancer in women and remains a leading cause of cancer-related morbidity, mortality, and resource utilization. For patients with advanced breast cancer, prognosis remains especially suboptimal, primarily because of acquired pharmacologic resistance.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State